Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic

Table 2 Chemotherapy and radiotherapy data for LRR/NP SCCHN patients undergoing reirradiation at Mayo Clinic

	Surgery/PRRT	DRRT	P
RRT + concurrent chemotherapy	28 (67)	32 (82)	0.11
Type
Cisplatin	17 (61)	7 (22)	0.002
Cetuximab	8 (29)	11 (34)
Cisplatin + cetuximab	0	3 (9)
Carboplatin	1 (3)	5 (16)
Other	2 (7)	6 (19)
Median primary radiotherapy dose	66 Gy (50–72 Gy)	66 Gy (26.4–79.2)	0.62
Median RRT dose	60 Gy (12–70 Gy)	69.6 Gy (48–76.8 Gy)	<0.0001
RRT dose
< 60 Gy	11 (26)	1 (3)	-
≥ 60 to < 70 Gy	25 (60)	8 (20)
≥ 70 Gy	6 (14)	30 (77)
Primary radiotherapy technique
IMRT	22 (52)	11 (28)	0.95
3D conformal	13 (31)	18 (46)
No information	7 (17)	10 (26)
RRT technique
IMRT	36 (86)	38 (97)	0.08
IMRT/IORT	3 (7)	0
3D conformal	3 (7)	1 (3)x

DRRT definitive reirradiation therapy, IMRT intensity modulated radiation therapy, IORT intra-operative radiation therapy, PRRT post-operative reirradiation therapy, RRT reirradiation

ISSN: 1748-717X